This article is 9 months old
Reactions: Cell therapy 'teaches' immune system to tolerate liver transplants, phase 1 trial shows

Currently, when an organ transplant is performed, the patient has to take immunosuppressive drugs to prevent his or her system from rejecting the new organ. These drugs must be taken for life and have numerous side effects. In a phase 1 clinical trial, researchers gave patients receiving a liver transplant regulatory dendritic cells derived from the original donor, with the hypothesis that these cells could 'teach' the recipient's immune system to tolerate the new organ. The research, published in Science Translational Medicine, suggests that this treatment could reduce or even eliminate the need for long-term use of immunosuppressants.

11/10/2023 - 20:00 CEST
Expert reactions

Marcos López Hoyos - trasplante hígado terapia celular EN

Marcos López Hoyos

President of the Spanish Society of Immunology (SEI) and former secretary of the Spanish Society of Transplantation (SET)

Science Media Centre Spain

This is a very relevant article from a phase 1a/2 trial to look at the clinical utility and immunological monitoring of patients who have received tolerogenic dendritic cells. The use of these cells as a mechanism to induce tolerance (acceptance of the transplanted graft) and reduce the burden of immunosuppression, which causes numerous long-term adverse effects, has been the 'holy grail' in organ transplantation for decades. 

This study demonstrates in a series of 16 liver transplant patients the beneficial effect of this treatment. It shows this at the level of safety and through the study of immune cell populations, not only in blood but also in the liver graft, which is where the immune response really takes place. They show a reduction of cells, such as natural killer and CD8+ T cells, with the capacity to cause graft rejection up to one year post-transplant follow-up.  

The data support the clinical use of these immune rejection regulatory or suppressor cells in liver transplantation.

The author has not responded to our request to declare conflicts of interest

Matesanz - Dendríticas (EN)

Rafael Matesanz

Creator and founder of the National Transplant Organisation.

Science Media Centre Spain

At the present time it can be said that the infusion of different types of immunomodulating cells from the donor, whether living (kidney or liver) or cadaveric (different solid organs), is one of the hot topics in transplant research, both to achieve better tolerance and less organ rejection in the short term and to reduce or eliminate immunosuppressive drugs in the medium and long term and thus achieve immunotolerance, the panacea of transplantation. 

The problem is that we do not know which type of cell is best, as well as the pattern of administration. The authors propose the administration of regulatory dendritic cells in one type of transplant, living donor liver transplantation, in a clinical trial in a still preliminary phase in which they have so far proven the safety of the method and have verified that one year later a series of immunological alterations induced by the dendritic cells are maintained, which could be indicative of a reduced need for immunosuppressants or even their withdrawal. The line of work has a certain amount of support from animal experimentation, but logically still lacks the clinical confirmation that would mean being able to effectively withdraw the immunosuppressants without the organ being rejected. 

In the meantime, this is a good work in an interesting line of work, but its conclusions are preliminary and will have to be verified with the extension of the trial and future research.

The author has declared they have no conflicts of interest
Donor-derived regulatory dendritic cell infusion modulates effector CD8+ T cell and NK cell responses after liver transplantation
  • Research article
  • Peer reviewed
  • Clinical trial
  • People
Science Translational Medicine
Publication date

Lillian M. Tran et al.

Study types:
  • Research article
  • Peer reviewed
  • Clinical trial
  • People
The 5Ws +1
Publish it